Latest News about CMPS
Recent news which mentions CMPS
Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript
February 29, 2024
Tickers
CMPS
From Motley Fool
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
From Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
From Benzinga
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
February 29, 2024
From Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
From Benzinga
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
February 27, 2024
From InvestorPlace
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
From InvestorPlace
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.
February 19, 2024
Tickers
CMPS
From Motley Fool
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
From Benzinga
Why Is MindMed (MNMD) Stock Up 8% Today?
February 12, 2024
From InvestorPlace
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?
February 02, 2024
Tickers
CMPS
From Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
From Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
From Benzinga
New Study Reveals Suggestibility's Role In Antidepressant Effects Of Psilocybin Therapy
January 25, 2024
Tickers
CMPS
From Benzinga
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
From Benzinga
From Benzinga
From InvestorPlace
3 Big New Catalysts for Psychedelics Stocks in 2024
January 08, 2024
From Motley Fool
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
From Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
From Benzinga
Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research
January 05, 2024
From Benzinga
AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect
January 03, 2024
From Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
From Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
From Benzinga
Do Psychedelic Treatments Always Require Psychotherapy? Well, We Need To Look 'Beyond Reductionism'
December 19, 2023
Tickers
CMPS
From Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
December 18, 2023
From Benzinga
MindMed’s stock boosted by positive data in trial of LSD as treatment for anxiety disorder
December 14, 2023
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.